Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 7/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.43 |
| ▸ | KLK1 | P06870 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189204 | 1.00 | DGAT2 (0.47) | DGAT2HRH3ADRA1AKLKB1KLK1 | |
| SCHEMBL2191783 | 0.95 | HRH3 (0.47) | DGAT2HRH3ADRA1AHRH1 | |
| SCHEMBL2267473 | 0.90 | ADRA1A (0.56) | DGAT2HRH3ADRA1AKLKB1KLK1 | |
| SCHEMBL2223790 | 0.90 | ADRA1A (0.56) | DGAT2HRH3ADRA1AKLKB1KLK1 | |
| SCHEMBL1788640 | 0.88 | HRH3 (0.45) | DGAT2HRH3KLKB1KLK1HRH1 | |
| SCHEMBL1787507 | 0.88 | HRH3 (0.45) | DGAT2HRH3KLKB1KLK1HRH1 | |
| SCHEMBL1787502 | 0.88 | HRH3 (0.45) | DGAT2HRH3KLKB1KLK1HRH1 | |
| SCHEMBL1788619 | 0.87 | HRH3 (0.48) | DGAT2HRH3HRH1 | |
| SCHEMBL2269495 | 0.85 | HRH3 (0.50) | HRH3ADRA1AKLKB1KLK1HRH1 | |
| SCHEMBL2266847 | 0.85 | HRH3 (0.50) | HRH3ADRA1AKLKB1KLK1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | claimed |
| WO-2011083314-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | WO | claimed |
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| WO-2011083314-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | HRH3, HRH4, HRH2 | DGAT2 4425/4885HRH3 1/4885ADRA1A 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.